Inside Alts: Private equity management fees hit new low in 2025

Inside Alts: Private equity management fees hit new low in 2025


A view of the New York Stock Exchange (NYSE) on Wall Street November 13, 2024, in New York City. 

Angela Weiss | AFP | Getty Images

A version of this article appeared in CNBC’s Inside Alts newsletter, a guide to the fast-growing world of alternative investments, from private equity and private credit to hedge funds and venture capital. Sign up to receive future editions, straight to your inbox.

Private equity firms that raised funds in 2025 charged the lowest average management fee rates ever recorded, continuing a multiyear downward trend. 

Buyout funds of last year’s vintage asked investors to pay a mean rate of 1.61% of assets, according to data through June from Preqin, published in a December report. That’s well below the legacy 2% management fee that the industry has been known for since its inception. 

There are a few reasons for this trend toward fee compression – and they’re not all dire. Of course, the industry has experienced a difficult few years of fundraising, requiring many managers to offer fee discounts to secure commitments. Even still, the industry raised $507 billion in aggregate capital across 856 funds during the first three quarters of 2025, which is expected to be essentially the same amount as 2024, when the final quarter of the year is tallied, according to Preqin. 

In response to a difficult fundraising environment, managers have been consolidating and capital is increasingly going toward the biggest funds. Nearly 46% of the capital raised in 2025 was done so by the 10 largest funds, up from 34.5% in 2024, according to PitchBook. 

The rise in prevalence of larger funds is also why fees are compressing. Funds seeking more than $1 billion contributed to dragging down the mean, while middle-market and newer, smaller firms charged closer to that 2% figure, Preqin data shows. Larger funds can spread fixed costs – such as compensation, compliance and technology – over a broader base. In other words, just because fee rates are lower doesn’t mean the fee dollars are. 

“In the near-to-medium term, we expect private-equity fee compression to continue,” Preqin’s Brigid Connor wrote in the report. “We believe the biggest driver of this trend is growing fund sizes.” 

Get Inside Alts directly to your inbox

However, Connor said it’s unclear whether fund sizes will grow large enough to the point where private equity fees fall to the levels of actively managed, public equity strategies. 

Preqin doesn’t break out details about incentive fees, which are typically paid when assets are sold or taken public, as a proportion of the appreciation. However, so-called realizations have been muted over the last few years after an onslaught of buyouts during 2020 and 2021 created a sizable backlog. Higher rates have increased the cost of capital – a headwind for managers seeking to monetize assets at higher valuations than they paid for them. 

That dynamic led to the challenging fundraising environment and also made it more difficult for managers to collect sizable incentive fees. 

There’s a broad expectation that could change in 2026 – especially if there are several more rate cuts from the Federal Reserve – and the gap between buyers and sellers of assets continues to narrow. 



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More